Home › NDC Lookup › RxCUI directory › RxCUI 1433734

Naftifine hydrochloride 0.02 MG/MG Topical Gel — RxCUI 1433734

RxNorm drug concept · Semantic clinical drug
RxCUI 1433734 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1433734
Official nameNaftifine hydrochloride 0.02 MG/MG Topical Gel
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnaftifine hydrochloride 2 % Topical Gel; naftifine HCl 2 % Topical Gel
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)637 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Naftifine Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Naftifine is an antifungal medicine applied to the skin to treat common fungal infections. The gel form (2%) is specifically approved for athlete's foot between the toes — that itc...
  • What exactly is naftifine used to treat?
  • Apply a thin layer once a day to the infected area plus a small border — about a half-inch — of the healthy skin around it. Treatment generally lasts 2 weeks. It's important to fin...
  • How do I apply it, and how long do I need to use it?
📖 Read our full Naftifine Topical guide →

🕸️ Concept Web — How Naftifine hydrochloride 0.02 MG/MG Topical Gel Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Naftifine hydrochloride 0.02 MG/MG Topical Gel RxCUI 1433734

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Naftifine 31476
    • Naftifine hydrochloride 91293
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Naftin 218564
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Naftifine Topical Gel 487271
    • Naftifine hydrochloride Topical Gel 2647550
    • Naftifine Topical Product 1158381
    • Naftifine hydrochloride Topical Product 2660562
    • Naftifine Topical Gel [Naftin] 370393
    • Naftifine hydrochloride Topical Gel [Naftin] 2654709
    • Naftin Topical Product 1177534
    • Topical Gel 346286
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Naftifine hydrochloride 0.02 MG/MG SCDC · 1433733
  • Naftifine Topical Gel SCDF · 487271
  • Naftifine hydrochloride Topical Gel SCDFP · 2647550
  • Naftifine Topical Product SCDG · 1158381
  • Naftifine hydrochloride Topical Product SCDGP · 2660562

Brand-Name Concepts

  • Naftifine hydrochloride 0.02 MG/MG Topical Gel [Naftin] SBD · 1433736
  • Naftifine hydrochloride 0.02 MG/MG [Naftin] SBDC · 1433735
  • Naftifine Topical Gel [Naftin] SBDF · 370393
  • Naftifine hydrochloride Topical Gel [Naftin] SBDFP · 2654709
  • Naftin Topical Product SBDG · 1177534
  • Naftin BN · 218564

📦 FDA Products & Package NDCs

3 products · 6 package NDCs
6 package NDCs map to RxCUI 1433734 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
51672-1376-03 1 TUBE in 1 CARTON (51672-1376-3) / 60 g in 1 TUBE Naftifine Hydrochloride Sun Pharmaceutical Industries, Inc. 2023-04-01
51672-1376-06 1 TUBE in 1 CARTON (51672-1376-6) / 45 g in 1 TUBE Naftifine Hydrochloride Sun Pharmaceutical Industries, Inc. 2023-04-01
54766-0772-45 1 TUBE in 1 CARTON (54766-772-45) / 45 g in 1 TUBE Naftin Sebela Pharmaceuticals Inc. 2018-03-01
54766-0772-60 1 TUBE in 1 CARTON (54766-772-60) / 60 g in 1 TUBE Naftin Sebela Pharmaceuticals Inc. 2018-03-01
83107-0023-45 1 TUBE in 1 CARTON (83107-023-45) / 45 g in 1 TUBE Naftin Legacy Pharma USA Inc. 2025-07-29
83107-0023-60 1 TUBE in 1 CARTON (83107-023-60) / 60 g in 1 TUBE Naftin Legacy Pharma USA Inc. 2025-07-29
Observed labelers: Legacy Pharma USA Inc. (2) · Sebela Pharmaceuticals Inc. (2) · Sun Pharmaceutical Industries, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.